Business Model Breakdown
How Plus Therapeutics Inc Makes Money
PSTV
Market Cap
$37M
Profit Margin
-429.4%
Employees
21
The Short Version
Plus Therapeutics is a clinical-stage pharmaceutical company dedicated to developing innovative targeted radiotherapeutics for difficult-to-treat cancers, particularly those in the central nervous system. Their lead product, REYOBIQ™ (rhenium-186 obisbemeda), is designed to deliver radiation directly to tumor cells, aiming for improved efficacy and reduced side effects compared to conventional treatments. The company generates limited revenue from grants but primarily funds its extensive research and development through dilutive equity financing. The long-term business model relies on successfully navigating clinical trials and regulatory approval processes to eventually commercialize its proprietary drug candidates, either independently or through partnerships, to generate significant sales or licensing revenue.
Where the Revenue Comes From
Grant revenue (~100% of current revenue, $5.2M in 2025)
Future drug sales/licensing post-FDA approval
Who buys: Currently funding bodies (NIH). Future: Hospitals, oncologists, and healthcare systems for approved therapies.
Why It Works (Competitive Advantages)
- ✔FDA Orphan Drug Designation for REYOBIQ™ (7 years market exclusivity post-approval)
- ✔NIH partnership provides validation and funding
- ✔Proprietary targeted radiotherapeutic platform for difficult-to-treat cancers
Economic Moat: Narrow (Intangible Assets (Proprietary technology, intellectual property), Regulatory (Orphan Drug Designation for specific indications))
What Our Analysis Says
DVR Score as of April 16, 2026
Plus Therapeutics (PSTV) retains its high-risk, high-reward profile, but its immediate financial health has significantly improved since the last analysis. The company's cash position increased to over $16 million in 2025, moving stockholders' equity from negative to positive $3.9 million, substantially extending its cash runway. This addresses the primary financial risk previously identified. Furthermore, REYOBIQ™ received FDA Orphan Drug Designation, a key regulatory milestone. While the net loss increased, the improved financial liquidity and strategic leadership appointments strengthen its ability to pursue crucial clinical trials. The 1-for-25 reverse stock split, while reflecting past stock performance, also resolved a Nasdaq listing concern. The potential for 10x growth remains contingent on binary clinical outcomes for its lead asset, targeting high-unmet-need oncology markets like rGBM. The improved financial footing provides a longer window for these critical catalysts to materialize, justifying a higher score despite continued operational losses and high clinical risk.